AI Governance for Life Sciences GxP Systems: Validation and Audit Guide
AI governance for GxP systems is not a separate regulatory framework. It extends existing computer system validation (CSV/CSA), 21 CFR Part 11 audit trail requirements, and EU Annex 11 controls to AI-enabled components in manufacturing, quality, clinical, and lab systems.
Core Controls for GxP AI Governance
Four architectural controls form the foundation for validating and inspecting AI agents in GxP environments.
Agent Identity
Distinct, attributable identities for AI agents separate from shared service accounts.
Least-Privilege Permissions
Tool-call access scoped to the minimum required for a defined task.
Audit Logging
Immutable, timestamped records of agent decisions and tool invocations.
Human Oversight
Documented override and escalation paths for AI-driven actions.
Agent Identity and Least-Privilege Design for CSV/CSA
Structuring agent identity and permissions correctly is a prerequisite for validation scope, not an afterthought. The following architectural principles support traceability and risk-based validation under GAMP 5.
-
Distinct agent identity
Each AI agent should have an identity separate from shared service accounts so actions can be attributed for audit purposes under Part 11 and Annex 11.
-
Least-privilege scoping
Tool-call access should be limited to the systems and data required for a defined task, narrowing the validation scope to what the agent can actually reach.
-
Independent, immutable logging
Agent inputs, decisions, and tool invocations should be logged outside the agent's own process to support reconstruction of AI-driven actions during inspection.
-
Version and configuration control
Model versions, prompts, and configurations should be under change control analogous to software change control under GAMP 5.
-
Human override capability
Escalation and override paths for AI-driven actions should be built into the permission model, consistent with EMA's emphasis on preserved human oversight.
Governance Controls for Inspection Readiness
- Assign an accountable system owner for AI component performance within the existing quality organization
- Document AI-specific risk assessments covering model behavior, drift, and decision transparency alongside standard CSV documentation
- Preserve and document human oversight and override capability for AI-driven actions in GxP processes
- Maintain an inspection-ready documentation package linking AI validation evidence to Part 11 and Annex 11 audit trail requirements
- Monitor for model or behavior drift post-deployment and record findings as part of ongoing lifecycle oversight
AI Governance as an Extension of Computer System Validation
No FDA or EMA document currently establishes a distinct regulatory category for AI validation. FDA's discussion papers on AI/ML in drug development and its January 2025 draft guidance on AI supporting regulatory decision-making, along with EMA's 2023 Reflection Paper on AI in the medicinal product lifecycle, each frame AI oversight as an extension of existing computer system validation and data integrity principles rather than a new regime. The operative binding requirements remain 21 CFR Part 11, EU GMP Annex 11, GAMP 5, and PIC/S data integrity guidance (PI 041).
For AI governance leaders, this means AI-enabled components in manufacturing, quality, clinical, and lab systems should be validated using the same risk-based logic FDA's Computer Software Assurance (CSA) guidance applies to conventional software, categorized under GAMP 5's existing risk framework, and documented with the same rigor Part 11 and Annex 11 require for any GxP computerized system. The practical challenge is interpretation: these frameworks were not written with autonomous, tool-calling AI agents in mind, and organizations must document how existing controls apply to agent-based architectures rather than waiting for AI-specific regulation to be finalized.
Why Agentic AI Creates an Audit Trail Gap
Part 11 requires secure, computer-generated, time-stamped audit trails that independently record operator actions creating, modifying, or deleting electronic records. Annex 11 imposes a parallel requirement for GMP-relevant changes to data. Both were drafted for systems where a human operator initiates a discrete, loggable action. AI agents that autonomously select tools, chain multiple calls, and make intermediate decisions before producing a final output do not map cleanly onto that model.
A single agent task may involve several tool invocations, none of which resembles a traditional operator edit, yet each may be GxP-relevant if it touches manufacturing, quality, or clinical data. Closing this gap requires audit logs that capture not just the final output but the sequence of inputs, decisions, and tool calls that produced it, recorded independently of the agent itself so the record cannot be altered by the same process it documents. This is consistent with ALCOA+ principles under PIC/S guidance, which require data to be attributable, contemporaneous, and enduring regardless of whether a human or an AI agent generated it.
Audit evidence for AI agents should be attributable and independent of the agent process: log inputs, intermediate decisions, and tool invocations, not only the final output.
Mapping AI Validation Into Existing Quality Systems
The questions below address how CSA, revalidation triggers, and runtime controls fit into existing GxP quality systems when AI agents are in scope.
Does CSA replace CSV for validating AI components?
No. CSA is a risk-based assurance approach FDA has promoted since 2022 for production and quality system software generally. It reduces reliance on exhaustive scripted testing but does not eliminate validation obligations, and it applies to AI components the same way it applies to conventional software.
What triggers revalidation of an AI agent in a GxP system?
Regulatory papers point to model updates, configuration changes, and detected behavior drift as events warranting revalidation, consistent with CSA's risk-based logic. Organizations should define these triggers explicitly rather than relying on fixed revalidation schedules.
How is runtime policy enforcement different from validation documentation?
Validation documentation demonstrates that a system was assessed and controlled before and during deployment. Runtime policy enforcement, such as scoped tool permissions and monitored agent actions, provides the ongoing technical control layer that generates the evidence validation documentation depends on.
Extend Runtime Controls to Your GxP AI Agents
Trussed AI provides runtime governance for enterprise AI agents, including agent identity, least-privilege permissions, tool approval workflows, and audit logging that can support GxP validation and audit evidence requirements.
Explore Runtime Governance